BioSpace News Archive

Naval Undersea Warfare Center (NUWC) Division utilizes 3D printing to supply face shields to CHI Franciscan

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Carrie Brownstein, M.D., to the role of Chief Medical Officer

After carrying out thorough research on arbovirus testing, Persistence Market Research has come up with interesting insights on the global market and has a published a new research report titled “Arbovirus Testing Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)”.

Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug conjugate (ADC) at the upcoming AACR Virtual Annual Meeting 2020.

Applied Biology, Inc. (“Applied Biology”) announced today it has licensed to Applied Botanics, LLC. (Louisville, KY) intellectual property rights to a novel cannabinoid based therapy under development for COVID-19 and other respiratory illnesses.

180,000 new claims processed for telephone and virtual visits in March, along with 50,000 new claims for COVID-19 testing and care

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce another successful transaction in its market-leading Healthcare / Life Sciences Consulting and Outsourcing Practice.

This year marks the 4th anniversary of the Public Health Excellence in Interprofessional Education Collaboration Award, which was established to acknowledge and celebrate outstanding multidisciplinary efforts to impact community health. The U.S. Public Health Service (USPHS) and the Interprofessional Education Collaborative (IPEC) are delighted to congratulate the 2020 USPHS IPEC Award winners and four honorable mention finalists.

Waters Corporation (NYSE:WAT) will webcast its Q1 2020 financial results conference call live on Tuesday, April 28th at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters’ website, www.waters.com choose “Investors” and click on the Live Webcast.

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia, is now available by prescription in the U.S.